You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name4-Androstenedione
Accession NumberDB01536  (EXPT00569, DB07386)
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionA delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol. [PubChem]
Structure
Thumb
Synonyms
4-Androstene-3,17-dione
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII409J2J96VR
CAS number63-05-8
WeightAverage: 286.4085
Monoisotopic: 286.193280076
Chemical FormulaC19H26O2
InChI KeyInChIKey=AEMFNILZOJDQLW-QAGGRKNESA-N
InChI
InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
IUPAC Name
(1S,2R,10R,11S,15S)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • Oxosteroid
  • 17-oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of action4-androstenedione is a 19-carbon steroid hormone produced in the adrenal glands and the gonads as an intermediate step in the biochemical pathway that produces the androgen testosterone and the estrogens estrone and estradiol.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Aromatase deficiencyDiseaseSMP00565
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9793
Caco-2 permeable+0.8011
P-glycoprotein substrateSubstrate0.5526
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6615
Renal organic cation transporterNon-inhibitor0.6632
CYP450 2C9 substrateNon-substrate0.8548
CYP450 2D6 substrateNon-substrate0.9131
CYP450 3A4 substrateSubstrate0.7193
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9387
CYP450 2D6 inhibitorNon-inhibitor0.9386
CYP450 2C19 inhibitorNon-inhibitor0.8138
CYP450 3A4 inhibitorNon-inhibitor0.8483
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8067
Ames testNon AMES toxic0.9508
CarcinogenicityNon-carcinogens0.9313
BiodegradationNot ready biodegradable0.9343
Rat acute toxicity1.5360 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7599
hERG inhibition (predictor II)Non-inhibitor0.7469
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158 °CPhysProp
water solubility57.8 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.75HANSCH,C ET AL. (1995)
logS-3.69ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.027 mg/mLALOGPS
logP2.93ALOGPS
logP3.93ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity83.61 m3·mol-1ChemAxon
Polarizability33.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.2 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MSsplash10-004l-5910000000-518e1ad38bcc73325b53View in MoNA
GC-MSGC-MS Spectrum - GC-MSsplash10-004l-5910000000-5172e05f9889ee2bfaf4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-000i-0090000000-36e848ba16b141eef47bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-052b-9600000000-712954fc35a84c8217deView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-052b-9300000000-f8e9aa16b4b208b69f7bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-000f-8940000000-e12025ea2b7808c64b9cView in MoNA
MSMass Spectrum (Electron Ionization)splash10-059m-3940000000-9cb32ac21e46afb2829aView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Angela M. H. Brodie, Harry J. Brodie, David A. Marsh, “Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis.” U.S. Patent US4235893, issued October, 1962.

US4235893
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 4-Androstenedione.
Aldesleukin4-Androstenedione may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of 4-Androstenedione can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of 4-Androstenedione can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 4-Androstenedione.
AmiodaroneThe serum concentration of 4-Androstenedione can be increased when it is combined with Amiodarone.
Amphotericin B4-Androstenedione may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of 4-Androstenedione can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of 4-Androstenedione.
BazedoxifeneThe serum concentration of 4-Androstenedione can be increased when it is combined with Bazedoxifene.
Bendroflumethiazide4-Androstenedione may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 4-Androstenedione.
Bismuth SubcitrateThe bioavailability of 4-Androstenedione can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of 4-Androstenedione can be increased when it is combined with Boceprevir.
Bumetanide4-Androstenedione may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 4-Androstenedione.
Calcium carbonateThe bioavailability of 4-Androstenedione can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of 4-Androstenedione can be decreased when it is combined with Carbamazepine.
Ceritinib4-Androstenedione may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of 4-Androstenedione can be increased when it is combined with Ceritinib.
Chlorothiazide4-Androstenedione may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of 4-Androstenedione can be increased when it is combined with Chlorotrianisene.
Chlorthalidone4-Androstenedione may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of 4-Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of 4-Androstenedione can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of 4-Androstenedione can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of 4-Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of 4-Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of 4-Androstenedione can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 4-Androstenedione.
CoumaphosThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Coumaphos.
DarunavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Dichlorvos.
DienestrolThe serum concentration of 4-Androstenedione can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of 4-Androstenedione can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with 4-Androstenedione.
Dihydrotestosterone4-Androstenedione may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Edrophonium.
EnzalutamideThe serum concentration of 4-Androstenedione can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of 4-Androstenedione can be increased when it is combined with Estradiol.
EstriolThe serum concentration of 4-Androstenedione can be increased when it is combined with Estriol.
EstroneThe serum concentration of 4-Androstenedione can be increased when it is combined with Estrone.
Etacrynic acid4-Androstenedione may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of 4-Androstenedione can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Fenthion.
Fluoxymesterone4-Androstenedione may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of 4-Androstenedione can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of 4-Androstenedione can be decreased when it is combined with Fosphenytoin.
Furosemide4-Androstenedione may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of 4-Androstenedione can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 4-Androstenedione.
HexestrolThe serum concentration of 4-Androstenedione can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 4-Androstenedione.
Hydrochlorothiazide4-Androstenedione may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide4-Androstenedione may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of 4-Androstenedione can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of 4-Androstenedione.
Indapamide4-Androstenedione may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with 4-Androstenedione.
ItraconazoleThe serum concentration of 4-Androstenedione can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of 4-Androstenedione can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of 4-Androstenedione can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with 4-Androstenedione.
MestranolThe serum concentration of 4-Androstenedione can be increased when it is combined with Mestranol.
Methyclothiazide4-Androstenedione may increase the hypokalemic activities of Methyclothiazide.
Methyltestosterone4-Androstenedione may increase the fluid retaining activities of Methyltestosterone.
Metolazone4-Androstenedione may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of 4-Androstenedione can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Minaprine.
MitotaneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of 4-Androstenedione.
NefazodoneThe serum concentration of 4-Androstenedione can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Neostigmine.
NevirapineThe serum concentration of 4-Androstenedione can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Nicorandil.
Oxandrolone4-Androstenedione may increase the fluid retaining activities of Oxandrolone.
Oxymetholone4-Androstenedione may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of 4-Androstenedione can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of 4-Androstenedione can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 4-Androstenedione.
PhenytoinThe serum concentration of 4-Androstenedione can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Physostigmine.
Piretanide4-Androstenedione may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of 4-Androstenedione can be increased when it is combined with Polyestradiol phosphate.
Polythiazide4-Androstenedione may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of 4-Androstenedione can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Pyridostigmine.
QuinestrolThe serum concentration of 4-Androstenedione can be increased when it is combined with Quinestrol.
Quinethazone4-Androstenedione may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of 4-Androstenedione.
RifabutinThe serum concentration of 4-Androstenedione can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of 4-Androstenedione can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of 4-Androstenedione can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 4-Androstenedione.
SaquinavirThe serum concentration of 4-Androstenedione can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 4-Androstenedione.
Stanozolol4-Androstenedione may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of 4-Androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of 4-Androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with 4-Androstenedione.
TelaprevirThe serum concentration of 4-Androstenedione can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of 4-Androstenedione can be increased when it is combined with Telithromycin.
Testosterone4-Androstenedione may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of 4-Androstenedione can be increased when it is combined with Tibolone.
Torasemide4-Androstenedione may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Trichlorfon.
Trichlormethiazide4-Androstenedione may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Tubocurarine.
VoriconazoleThe serum concentration of 4-Androstenedione can be increased when it is combined with Voriconazole.
Warfarin4-Androstenedione may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of 4-Androstenedione can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Testosterone dehydrogenase (nad+) activity
Specific Function:
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
Gene Name:
HSD17B1
Uniprot ID:
P14061
Molecular Weight:
34949.715 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Steroid delta-isomerase activity
Specific Function:
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids. Efficiently catalyzes the transformation of pregnenolone to progesterone, 17-alpha-hydroxypregnenolone to 17-alpha-hydroxypr...
Gene Name:
HSD3B1
Uniprot ID:
P14060
Molecular Weight:
42251.25 Da
References
  1. Ishii-Ohba H, Inano H, Tamaoki B: Purification and properties of testicular 3 beta-hydroxy-5-ene-steroid dehydrogenase and 5-ene-4-ene isomerase. J Steroid Biochem. 1986 Oct;25(4):555-60. [PubMed:2945972 ]
Kind
Protein
Organism
Saccharopolyspora erythraea (strain NRRL 23338)
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
Specific Function:
Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredoxin and a ferredoxin reductase for the transfer of electrons from NADPH to the monooxygenase.
Gene Name:
eryF
Uniprot ID:
Q00441
Molecular Weight:
45098.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function:
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms andro...
Gene Name:
AKR1C3
Uniprot ID:
P42330
Molecular Weight:
36852.89 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23